Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 692 participants.
Also called NCT04885218
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 692 participants
- Registry
-
NCT04885218
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04885218. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-30 (actual); primary completion 2023-05-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
- Condition
- Non-familial Hypercholesterolemia
- Condition
- Mixed Hyperlipidemia
- Intervention (Drug)
- SHR-1209 ;placebo
- Intervention (Drug)
- SHR-1209 ;placebo
- Intervention (Drug)
- SHR-1209 ;placebo
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct04885218- Content hash
bc354ea6f62069c70fca5fe17df56e5f31ba3524bb82104b295ea654676eb71e